Documented cause
Calibrate was founded in 2019 by Isabelle Kenyon in New York. The concept was a doctor-supervised metabolic health program combining GLP-1 receptor agonist medications (initially liraglutide/Saxenda, later semaglutide/Ozempic and Wegovy) with behavioral coaching to achieve sustainable weight loss without the rebound effect of diet-only programs. Calibrate's model was clinically differentiated: a physician-supervised protocol, weekly coaching check-ins, and a commitment to metabolic health metrics beyond weight (A1C, blood pressure, insulin resistance). The company raised $123M from ACME Capital, SV Angel, Forerunner Ventures, and others. The program was structured as a year-long subscription at approximately $136/month, with the patient responsible for GLP-1 medication costs (typically $800-$1,000+/month before insurance). The unit economics were structurally fatal. GLP-1 medications are among the most expensive drugs in the US healthcare system. Calibrate could not negotiate pharmaceutical pricing for its patients. Insurance coverage for GLP-1 for weight loss was inconsistent: many commercial plans refused coverage (vs. coverage for diabetes), meaning patients paid full retail. The total patient cost (subscription + medication) often exceeded $1,000/month. Calibrate could not retain patients at this cost level, and customer acquisition costs were high due to the complexity of the proposition. The market shifted rapidly against Calibrate when Eli Lilly and Novo Nordisk launched direct-to-consumer GLP-1 programs through compounding pharmacies, and Hims & Hers, Ro, and telehealth platforms entered the space at lower price points. In March 2024, Calibrate announced it was shutting down its metabolic health program, giving current patients 30 days to find alternative providers. The company could not be converted to a sustainable model. Approximately 200 employees lost their positions.
Alternative account: Calibrate was founded in New York in 2020 to offer a telehealth-based metabolic health programme combining GLP-1 medications (like Ozempic), behaviour coaching, and nutrition support. The company raised $130M from Forerunner Ventures, Oak HC/FT, and others. The programme cost $1,649/year and was positioned as a comprehensive alternative to traditional diet and weight loss approaches. The unit economics proved unworkable: the cost of physician consultations, medication management, coaching, and customer acquisition exceeded revenue per patient. Insurance reimbursement for GLP-1 medications was inconsistent and coverage was frequently denied. The company shut down abruptly in August 2023, leaving thousands of patients in the middle of ongoing treatment programmes.